Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 2.30%

Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has an Asset Resilience Ratio of 2.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥156.90 Million

≈ $22.96 Million USD Cash + Short-term Investments

Total Assets

CN¥6.82 Billion

≈ $997.38 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. See Sinopep-Allsino Biopharmaceutical Co. Lt free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Sinopep-Allsino Biopharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sinopep-Allsino Biopharmaceutical Co. Lt market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥156.90 Million	2.3%
Total Liquid Assets	CN¥156.90 Million	2.30%

Asset Resilience Insights

Limited Liquidity: Sinopep-Allsino Biopharmaceutical Co. Ltd. A maintains only 2.30% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Sinopep-Allsino Biopharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Prostemics Co. Ltd KQ:203690	Biotechnology	0.31%
ORUM KQ:475830	Biotechnology	82.74%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
TG Therapeutics Inc NASDAQ:TGTX	Biotechnology	4.72%
Green Cross Holdings Preference Shares KO:005257	Biotechnology	0.50%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	33.70%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Cybin Inc NEO:CYBN	Biotechnology	0.21%

Annual Asset Resilience Ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Sinopep-Allsino Biopharmaceutical Co. Ltd. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.72%	CN¥116.00 Million ≈ $16.97 Million	CN¥6.74 Billion ≈ $986.32 Million	-2.38pp
2024-12-31	4.10%	CN¥208.00 Million ≈ $30.44 Million	CN¥5.08 Billion ≈ $743.07 Million	+2.39pp
2022-12-31	1.71%	CN¥43.01 Million ≈ $6.29 Million	CN¥2.52 Billion ≈ $369.09 Million	-2.39pp
2021-12-31	4.10%	CN¥87.13 Million ≈ $12.75 Million	CN¥2.13 Billion ≈ $311.23 Million	-1.64pp
2020-12-31	5.73%	CN¥80.00 Million ≈ $11.71 Million	CN¥1.40 Billion ≈ $204.22 Million	--

pp = percentage points

About Sinopep-Allsino Biopharmaceutical Co. Ltd. A

SHG:688076 China Biotechnology

Market Cap

$1.27 Billion

CN¥8.70 Billion CNY

Market Cap Rank

#7852 Global

#1778 in China

Share Price

CN¥27.52

Change (1 day)

-1.15%

52-Week Range

CN¥26.25 - CN¥46.88

All Time High

CN¥90.43